- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
PIK3CA / P110alpha AntibodyPeptide-affinity purified goat antibody
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AF1827a | 0.1mg 400 ul | 7-10 days | $ 325.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
PIK3CA / P110alpha Antibody - Product info | |
| Other Accession | NP_006209 |
| Reactivity | Human |
| Concentration | 100ug/200ul |
| Isotype | IgG |
PIK3CA / P110alpha Antibody - Additional info | |
| Other Names PIK3CA; p110-alpha; phosphoinositide-3-kinase, catalytic, alpha polypeptide ; MGC142161; MGC142163; PI3K; PI3-kinase p110 subunit alpha; PtdIns-3-kinase p110; phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha; phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit, alpha isoform | |
| Format 0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions PIK3CA / P110alpha Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
PIK3CA / P110alpha Antibody - Application data
-
AF1827a (2.5 µg/ml) staining of paraffin embedded Human Brain (Cerebellar Cortex). Steamed antigen retrieval with citrate buffer pH 6, AP-staining.
PIK3CA / P110alpha Antibody - Related products
AP8016c: PI3KCA Antibody (Center)
AP3558a: Phospho-PK3CA-pY317 Antibody
AP7860a: PK3CA Antibody (Y317)
AP8016a: PI3KCA Antibody (N-term)
AP8016b: PI3KCA Antibody (C-term)
RI13994: PIK3CA predesign siRNA
BP3558a: Phospho-PK3CA-pY317 Antibody Blocking Peptide
BP7860a: PK3CA Antibody (Y317) Blocking Peptide
BP8016a: PI3KCA Antibody (N-term) Blocking Peptide
BP8016b: PI3KCA Antibody (C-term) Blocking Peptide
BP8016c: PI3KCA Antibody (Center) Blocking Peptide
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers.
REFERENCES
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Bruckman KC, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010 Aug 31. PMID 20813562. NRAS mutations are rare in colorectal cancer. Irahara N, et al. Diagn Mol Pathol, 2010 Sep. PMID 20736745. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Liao W, et al. Anat Rec (Hoboken), 2010 Sep. PMID 20652941. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Slattery ML, et al. Carcinogenesis, 2010 Sep. PMID 20622004.
